These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 31296227)
1. Integrative genomic and transcriptomic analysis of genetic markers in Dupuytren's disease. Jung J; Kim GW; Lee B; Joo JWJ; Jang W BMC Med Genomics; 2019 Jul; 12(Suppl 5):98. PubMed ID: 31296227 [TBL] [Abstract][Full Text] [Related]
2. Molecular phenotypic descriptors of Dupuytren's disease defined using informatics analysis of the transcriptome. Rehman S; Salway F; Stanley JK; Ollier WE; Day P; Bayat A J Hand Surg Am; 2008 Mar; 33(3):359-72. PubMed ID: 18343292 [TBL] [Abstract][Full Text] [Related]
3. Whole genome and global expression profiling of Dupuytren's disease: systematic review of current findings and future perspectives. Shih B; Watson S; Bayat A Ann Rheum Dis; 2012 Sep; 71(9):1440-7. PubMed ID: 22772327 [TBL] [Abstract][Full Text] [Related]
4. Expression of a novel gene, MafB, in Dupuytren's disease. Lee LC; Zhang AY; Chong AK; Pham H; Longaker MT; Chang J J Hand Surg Am; 2006 Feb; 31(2):211-8. PubMed ID: 16473681 [TBL] [Abstract][Full Text] [Related]
5. Identification of biomarkers in Dupuytren's disease by comparative analysis of fibroblasts versus tissue biopsies in disease-specific phenotypes. Shih B; Wijeratne D; Armstrong DJ; Lindau T; Day P; Bayat A J Hand Surg Am; 2009 Jan; 34(1):124-36. PubMed ID: 19121738 [TBL] [Abstract][Full Text] [Related]
6. RNA sequencing reveals a depletion of collagen targeting microRNAs in Dupuytren's disease. Riester SM; Arsoy D; Camilleri ET; Dudakovic A; Paradise CR; Evans JM; Torres-Mora J; Rizzo M; Kloen P; Julio MK; van Wijnen AJ; Kakar S BMC Med Genomics; 2015 Oct; 8():59. PubMed ID: 26446724 [TBL] [Abstract][Full Text] [Related]
7. Microarray analysis of Dupuytren's disease cells: the profibrogenic role of the TGF-β inducible p38 MAPK pathway. Ratkaj I; Bujak M; Jurišić D; Baus Lončar M; Bendelja K; Pavelić K; Kraljević Pavelić S Cell Physiol Biochem; 2012; 30(4):927-42. PubMed ID: 22965824 [TBL] [Abstract][Full Text] [Related]
8. Genome-wide analysis using exon arrays demonstrates an important role for expression of extra-cellular matrix, fibrotic control and tissue remodelling genes in Dupuytren's disease. Forrester HB; Temple-Smith P; Ham S; de Kretser D; Southwick G; Sprung CN PLoS One; 2013; 8(3):e59056. PubMed ID: 23554969 [TBL] [Abstract][Full Text] [Related]
9. Dupuytren's: a systems biology disease. Rehman S; Goodacre R; Day PJ; Bayat A; Westerhoff HV Arthritis Res Ther; 2011; 13(5):238. PubMed ID: 21943049 [TBL] [Abstract][Full Text] [Related]
11. A meta-analysis to identify novel diagnostic and therapeutic targets for Dupuytren's disease. Park TH; Kim D; Lee YS; Kim SY Wound Repair Regen; 2020 Mar; 28(2):202-210. PubMed ID: 31688987 [TBL] [Abstract][Full Text] [Related]
12. Developing an animal model of Dupuytren's disease by orthotopic transplantation of human fibroblasts into athymic rat. Satish L; Palmer B; Liu F; Papatheodorou L; Rigatti L; Baratz ME; Kathju S BMC Musculoskelet Disord; 2015 Jun; 16():138. PubMed ID: 26049932 [TBL] [Abstract][Full Text] [Related]
13. Exploring the potential relationship between frozen shoulder and Dupuytren's disease through bioinformatics analysis and machine learning. Ouyang Y; Chen S; Tu Y; Wan T; Fan H; Sun G Front Immunol; 2023; 14():1230027. PubMed ID: 37720213 [TBL] [Abstract][Full Text] [Related]
14. Functional genomics in identification of drug targets in Dupuytren's contracture. Sedic M; Jurisic D; Stanec Z; Hock K; Pavelic K; Kraljevic Pavelic S Front Biosci (Landmark Ed); 2010 Jan; 15(1):57-64. PubMed ID: 20036806 [TBL] [Abstract][Full Text] [Related]
15. Using functional genomics to identify drug targets: a Dupuytren's disease example. Sedic M; Pavelic SK; Hock K Methods Mol Biol; 2012; 910():15-31. PubMed ID: 22821590 [TBL] [Abstract][Full Text] [Related]
16. Wnt expression is not correlated with beta-catenin dysregulation in Dupuytren's Disease. O'Gorman DB; Wu Y; Seney S; Zhu RD; Gan BS J Negat Results Biomed; 2006 Aug; 5():13. PubMed ID: 16942611 [TBL] [Abstract][Full Text] [Related]
17. Genetic susceptibility in Dupuytren's disease: lack of association of a novel transforming growth factor beta(2) polymorphism in Dupuytren's disease. Bayat A; Alansar A; Hajeer AH; Shah M; Watson JS; Stanley JK; Ferguson MW; Ollier WE J Hand Surg Br; 2002 Feb; 27(1):47-9. PubMed ID: 11895345 [TBL] [Abstract][Full Text] [Related]
18. Genetics of Dupuytren's disease. Michou L; Lermusiaux JL; Teyssedou JP; Bardin T; Beaudreuil J; Petit-Teixeira E Joint Bone Spine; 2012 Jan; 79(1):7-12. PubMed ID: 21803632 [TBL] [Abstract][Full Text] [Related]
19. Dupuytren's disease therapy: targeting the vicious cycle of myofibroblasts? Musumeci M; Vadalà G; Russo F; Pelacchi F; Lanotte A; Denaro V Expert Opin Ther Targets; 2015; 19(12):1677-87. PubMed ID: 26690790 [TBL] [Abstract][Full Text] [Related]
20. The expression of myoglobin and ROR2 protein in Dupuytren's disease. Forsman M; Pääkkönen V; Tjäderhane L; Vuoristo J; Kallioinen L; Salo T; Kallioinen M; Ryhänen J J Surg Res; 2008 May; 146(2):271-5. PubMed ID: 17996904 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]